Lori A. Leslie, MD, Hackensack University Medical Center

Articles

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

May 14th 2024

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

January 4th 2024

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

The Future of the Treatment Landscape in MZL and FL

May 18th 2021

Key opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.

Sequencing Algorithms for Umbralisib-Based Therapy in MZL and FL

May 18th 2021

Experts in the management of lymphoma discuss how umbralisib fits into sequencing algorithms and highlight how treatment decisions are particularly complex in MZL compared to FL.

Combination Therapy With Umbralisib in MZL and FL

May 11th 2021

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, comment on the potential safety and efficacy of the PI3K inhibitor umbralisib in combination with a CD20 antibody in marginal zone and follicular lymphoma.

The UNITY-NHL Trial of Umbralisib in MZL and FL

May 11th 2021

Key opinion leaders in hematology-oncology discuss the recent UNITY-NHL trial and the FDA’s accelerated approval of umbralisib in relapsed/refractory marginal zone lymphoma and follicular lymphoma.

Safety and Efficacy of PI3K Inhibitors in MZL and FL

May 4th 2021

Expert hematologist-oncologists share insights about the role of PI3K inhibition and immunosuppression in indolent non-Hodgkin lymphoma and review the safety and efficacy of idelalisib, duvelisib, and copanlisib.

Second-Line Chemoimmunotherapy for MZL and FL

May 4th 2021

Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, consider treatment options for patients with relapsed/refractory disease after first-line chemoimmunotherapy.

First-Line Chemoimmunotherapy for MZL and FL

April 27th 2021

Key opinion leaders in hematology-oncology discuss treatment considerations for first-line chemoimmunotherapy in follicular lymphoma and marginal zone lymphoma and when to use maintenance therapy or observation.

Factors to Consider When Initiating Treatment for MZL and FL

April 27th 2021

Experts in lymphoma provide insight into factors to consider when initiating treatment and emphasize the importance of both clinical judgment and treatment guidelines like the GELF criteria when monitoring patients.

Diagnosis of Indolent Lymphomas: MZL vs FL

April 20th 2021

Experts in hematology-oncology build a discussion on differences in patient presentation and diagnosis of different types of indolent non-Hodgkin lymphomas such as marginal zone lymphoma and follicular lymphoma.

Epidemiology, Etiology, and Risk Factors for Lymphoma

April 20th 2021

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, discuss the epidemiology, etiology, and risk factors for different types of lymphoma and provide key insights into those classified as indolent non-Hodgkin’s lymphoma.